Savaysa (Edoxaban Tosylate) Patent Expiration, LOE Window & CMS Spending

Savaysa (Edoxaban Tosylate) by Daiichi Sankyo: FDA Orange Book core substance LOE 2027-04-18 (last listed 2028-03-28), 0 AB generics, $5.6M 2024 CMS Part D & Medicaid spend, and 6 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorDaiichi Sankyo
FDA Application & PathwayN206316 (NDA)
Exclusivity / Cliff HorizonNear-Term Cliff (2028-2030)
Core Active-Ingredient LOE Date2027-04-18
Last Listed Patent or Exclusivity Date2028-03-28
Orange Book Patents (*PED Extensions)2 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$5.6M
2024 Medicare Part D Spend$5.1M
2024 Medicaid Spend$512K
Reported Wholesale Price Change (CA SB 17)6 WAC filings (max 18.0% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Daiichi Sankyo across sibling Meru public-data platforms.